Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rare heart cancer under the microscope: italian study seeks answers

NCT ID NCT05819528

Knowledge-focused Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 2 times

Summary

This study looks back at 43 cases of primary cardiac lymphoma, a very rare cancer that starts in the heart. Researchers want to learn how the disease behaves and how it has been treated in Italy over the past 20 years. The goal is to find patterns that can help doctors make better decisions for future patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 43 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient affected by primary cardiac lymphoma from 1st January 2000 to 31st December 2020.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of PCL (any histotype) defined as an extranodal lymphoma involving only the heart with possible involvement of the pericardium. * Age ≥18 years. * Diagnosis histologically confirmed. Cytofluorimetry analysis of pericardial fluid showing phenotypic features consistent with a primary cardiac lymphoma is permitted if a biopsy sample is not feasible/available for diagnosis; monoclonality is not accepted as a surrogate for diagnosis. * Date of diagnosis: from 1st January 2000 to 31st December 2020. * Only patients treated in first-line with chemoimmunotherapy regimens including an anti-CD20 monoclonal antibody are eligible for the study. * Signed written informed consent (in case of unreachable subject please see chapter 11.2) Exclusion Criteria: * Secondary cardiac involvement from lymphoma; primary mediastinal lymphoma with pericardial infiltration or other lymphomas with involvement of the pericardium/the heart by contiguity and primary effusion lymphoma are not included in this study. * Patients treated with chemotherapy regimens that did not include an anti-CD20 monoclonal antibody as first-line therapy. * Refuse to sign a written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary cardiac lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary cardiac lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O.U. Città della Salute e della Scienza di Torino - Ematologia Universitaria

    NOT_YET_RECRUITING

    Torino, Torino, 10126, Italy

  • AO Sant'Andrea - Ematologia

    RECRUITING

    Roma, Roma, 00183, Italy

  • AOU Integrata di Verona - U.O. Ematologia

    RECRUITING

    Verona, Verona, 37134, Italy

  • AOU Pisana - U.O. Ematologia

    NOT_YET_RECRUITING

    Pisa, Pisa, 56126, Italy

  • AOU di Sassari - Ematologia

    RECRUITING

    Sassari, SS, 07100, Italy

  • ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia

    RECRUITING

    Milan, Milano, 20162, Italy

  • ASST Spedali Civili di Brescia - Ematologia

    RECRUITING

    Brescia, Brescia, 25123, Italy

  • Azienda Ospedaliera Papa Giovanni XXIII - Ematologia

    RECRUITING

    Bergamo, Bergamo, 24127, Italy

  • Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna - Ematologia e fisiopatologia della coagulazione

    RECRUITING

    Ferrara, Ferrara, 44124, Italy

  • Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) - SC Ematologia

    RECRUITING

    Trieste, TS, 34121, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Ematologia

    RECRUITING

    Milan, Milano, 20133, Italy

  • Istituto Scientifico San Raffaele - Unitа Linfomi - Dipartimento Oncoematologia

    RECRUITING

    Milan, Milano, 20132, Italy

  • Ospedale S. Maria della Misericordia - Ematologia

    RECRUITING

    Perugia, Perugia, 06129, Italy